MDxHealth Reports Q3-2022 Results
Excluding the Oncotype DX GPS revenues, total revenues were $20.8 million, an increase of 28% compared to the first nine months of 2021.
- Excluding the Oncotype DX GPS revenues, total revenues were $20.8 million, an increase of 28% compared to the first nine months of 2021.
- Gross profit for the three months ended September 30, 2022, was $6.2 million, an increase of 143% as compared to $2.6 million for the three months ended September 30, 2021.
- Mr. McGarrity concluded, Todays results reflect our previously communicated view that mdxhealth is fast becoming a leading precision diagnostics company that can deliver sustainable growth.
- Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment.